A. Osinusi

720 total citations
15 papers, 146 citations indexed

About

A. Osinusi is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, A. Osinusi has authored 15 papers receiving a total of 146 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hepatology, 7 papers in Epidemiology and 6 papers in Rheumatology. Recurrent topics in A. Osinusi's work include Hepatitis C virus research (12 papers), Systemic Lupus Erythematosus Research (6 papers) and Liver Disease Diagnosis and Treatment (6 papers). A. Osinusi is often cited by papers focused on Hepatitis C virus research (12 papers), Systemic Lupus Erythematosus Research (6 papers) and Liver Disease Diagnosis and Treatment (6 papers). A. Osinusi collaborates with scholars based in Germany and United States. A. Osinusi's co-authors include Henry Masur, Ludmila Prokunina‐Olsson, Thomas R. OʼBrien, Dimitra Bon, Shyamasundaran Kottilil, Eva Herrmann, Eric G. Meissner, Wei Tang, Diana M. Brainard and Federico Hinestrosa and has published in prestigious journals such as The Journal of Infectious Diseases and Journal of Hepatology.

In The Last Decade

A. Osinusi

12 papers receiving 140 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Osinusi Germany 5 137 113 27 24 15 15 146
C John Germany 7 136 1.0× 131 1.2× 25 0.9× 15 0.6× 5 0.3× 21 160
Leonie Grellier United Kingdom 5 145 1.1× 132 1.2× 24 0.9× 45 1.9× 11 0.7× 6 189
Santos del Campo Spain 7 95 0.7× 87 0.8× 10 0.4× 14 0.6× 12 0.8× 21 133
Carola Mix Germany 6 303 2.2× 288 2.5× 20 0.7× 37 1.5× 13 0.9× 13 320
Nicole M. F. van Gerven Netherlands 4 220 1.6× 178 1.6× 36 1.3× 7 0.3× 10 0.7× 4 235
A. Yosry Egypt 7 245 1.8× 220 1.9× 15 0.6× 20 0.8× 4 0.3× 19 268
U. Kullig Germany 5 90 0.7× 79 0.7× 12 0.4× 6 0.3× 5 0.3× 7 98
Pascal Migaud Germany 3 63 0.5× 56 0.5× 16 0.6× 7 0.3× 10 0.7× 8 82
Aimilia Karampatou Italy 3 115 0.8× 106 0.9× 18 0.7× 10 0.4× 11 0.7× 3 154
Pascale Aumont France 6 286 2.1× 258 2.3× 36 1.3× 29 1.2× 5 0.3× 6 298

Countries citing papers authored by A. Osinusi

Since Specialization
Citations

This map shows the geographic impact of A. Osinusi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Osinusi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Osinusi more than expected).

Fields of papers citing papers by A. Osinusi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Osinusi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Osinusi. The network helps show where A. Osinusi may publish in the future.

Co-authorship network of co-authors of A. Osinusi

This figure shows the co-authorship network connecting the top 25 collaborators of A. Osinusi. A scholar is included among the top collaborators of A. Osinusi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Osinusi. A. Osinusi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Doyle, Joseph, et al.. (2018). Evaluation of APRI index to identify cirrhosis prior to direct-acting antiviral HCV treatment. Journal of Hepatology. 68. S313–S314. 2 indexed citations
2.
Kim, W. Ray, et al.. (2018). Survival benefits of direct-acting antiviral therapy in patients with decompensated hepatitis C cirrhosis. Journal of Hepatology. 68. S84–S84. 2 indexed citations
3.
Chokkalingam, Anand P., et al.. (2018). Risk of total non-hepatic cancer following treatment for HCV infection with direct-acting antiviral agents. Journal of Hepatology. 68. S86–S86.
4.
Ebeid, Fatma Soliman Elsayed, Abdel‐Rahman N. Zekri, Benedetta Massetto, et al.. (2018). Ledipasvir/Sofosbuvir for 12 weeks is safe and effective in adolescents with chronic hepatitis C virus infection and hematological malignancies undergoing chemotherapy. Journal of Hepatology. 68. S515–S515. 4 indexed citations
5.
Mangia, Alessandra, E. Läwitz, Edward Gane, et al.. (2018). Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with sofosbuvir-based regimens. Journal of Hepatology. 68. S67–S68. 13 indexed citations
6.
7.
Singer, A., A. Osinusi, Diana M. Brainard, & Anand P. Chokkalingam. (2017). Risk of cardiovascular and cerebrovascular events in hepatitis C patients following completion of direct-acting antiviral therapy: a retrospective cohort study. Journal of Hepatology. 66(1). S282–S283. 8 indexed citations
8.
Wilson, Eleanor, Perica Davitkov, Paul Y. Kwo, et al.. (2017). Real world effectiveness of 8 vs 12 weeks of ledipasvir/sofosbuvir (LDV/SOF) in blacks with HCV: A comparative analysis of clinical trials with real world cohorts.. 66. 1 indexed citations
9.
Bourlière, Marc, K N Agarwal, Eric Lawitz, et al.. (2017). Sustained viral response following treatment with direct acting antiviral agents for chronic hepatitis C and the risk of hepatocellular carcinoma. Journal of Hepatology. 66(1). S491–S492. 2 indexed citations
10.
Gane, Edward, K. Peter Etzkorn, G. Morelli, et al.. (2016). Sofosbuvir/Velpatasvir in Combination with Ribavirin for 24 Weeks is Effective Retreatment for Patients who failed Prior NS5A Containing DAA Regimens: Results of the GS-US-342-1553 Study. Journal of Hepatology. 64(2). S147–S148. 23 indexed citations
11.
Asselah, Tarik, Stephen Shafran, Sharon Bourgeois, et al.. (2016). Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in HCV Infected Patients Previously Treated with Placebo: Results of the Deferred Treatment Study (GS-US-342-1446 Study). Journal of Hepatology. 64(2). S827–S828. 1 indexed citations
12.
13.
Brown, Robert S., K. Rama Reddy, Jonathan M. Fenkel, et al.. (2016). Baseline Clinical and Laboratory Parameters Associated with Clinical Benefits of Successful HCV Treatment with Sofosbuvir/Velpatasvir in Decompensated Cirrhotic Patients. Journal of Hepatology. 64(2). S774–S774. 3 indexed citations
14.
Osinusi, A., Kerry Townsend, Amy Nelson, et al.. (2014). O11 RETREATMENT OF RELAPSERS TO SOFOSBUVIR/RIBAVIRIN WITH SOFOSBUVIR/LEDIPASVIR: COMPLETE AND RAPID VIROLOGIC SUPPRESSION BY WEEK 4. Journal of Hepatology. 60(1). S5–S6. 6 indexed citations
15.
Meissner, Eric G., Dimitra Bon, Ludmila Prokunina‐Olsson, et al.. (2013). IFNL4-ΔG Genotype Is Associated With Slower Viral Clearance in Hepatitis C, Genotype-1 Patients Treated With Sofosbuvir and Ribavirin. The Journal of Infectious Diseases. 209(11). 1700–1704. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C John Breakdown of academic impact, for papers by Leonie Grellier Breakdown of academic impact, for papers by Santos del Campo Breakdown of academic impact, for papers by Carola Mix Breakdown of academic impact, for papers by Nicole M. F. van Gerven Breakdown of academic impact, for papers by A. Yosry Breakdown of academic impact, for papers by U. Kullig Breakdown of academic impact, for papers by Pascal Migaud Breakdown of academic impact, for papers by Aimilia Karampatou Breakdown of academic impact, for papers by Pascale Aumont
Rankless by CCL
2026